Castle Creek Pharmaceuticals in New Jersey has reached an agreement to acquire Fibrocell Science, the Exton-based biotechnology company, for $63.3 million, writes John…

Fibrocell Science in Exton is seeking approval from the FDA to start human testing of its experimental treatment for scleroderma, a rare autoimmune skin disorder…

Chester County Hero Fund

James Vito, who recently retired as Chester County’s chief county detective after logging 37 years in the District Attorney’s…

With a trio of potential solutions for rare skin diseases being studied or soon to be studied on humans, an Exton research firm took the…

After investing almost $3 million more cash in its operations, including $1 million more than the same quarter a year ago for gene therapy research…

The Wharton School alumnus and experienced chief financial officer Keith A. Goldan will stick around in Chester County in the wake of a major deal…

Kimberly M. Smith is new interim chief financial officer, treasurer and corporate secretary at Fibrocell Science, Inc.

David Pernock, Fibrocell’s chairman and CEO, thanked…

Its been a busy week for the people at Fibrocell, the Exton based autologous cell therapy company focused on developing first-in-class treatments for…

Institutional investors and equity analysts are invited to a research and development day in New York on Sept. 24 sponsored by Fibrocell Science of Exton…

In a move to attract investors, Fibrocell Science, Inc. of Exton is transferring its U.S. stock exchange listing from the New York Stock Exchange…